What the Wegovy price cut means for employer sponsored health insurance March 2, 2026 Summary: Novo Nordisks planned 2027 cut to Wegovys list price may lower out-of-pocket costs for some patients, but because employer spending depends on net prices after rebates, it is unlikely to reduce overall employer costs or significantly expand coverage
Some states have "discovery rules" that extend the window in cases where the cause was not immediately apparent
They are out in the waiting room and I cant even recognize them
Denmark does not have an official cost-effectiveness threshold by which to determine whether a treatment is cost-effective, but a threshold of 357,000 DKK (around 50,000) per QALY is sometimes assumed [53,54,55]
From your first consultation to your ongoing care, our focus is helping you achieve real results with a team that truly cares about your health and your journey